Ryvu Therapeutics at ENA 2026
Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website
Ryvu Therapeutics brings 2 presentations to ENA 2026 in Barcelona. Its posters cover a new payload for antibody-drug conjugates and a search for drug targets in colorectal cancer. RVU602 is a cytotoxic and immunomodulatory payload that is neither a TOP1 nor a tubulin agent, and ONCO Prime is used to map hidden vulnerabilities in genetically stratified colorectal cancer.
| Organization | ENA 2026 Attendance |
|---|---|
Ryvu Therapeutics Kraków, Poland | |
Clinical-stage company developing small-molecule cancer drugs, including kinase inhibitors and synthetic lethality programs. | Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm |
Instantly find 20 buyers from Ryvu Therapeutics
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by EORTC, the NCI or the AACR. Submit a correction